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LETTERS TO THE EDITOR
Additional antiretroviral and
immunosuppressive drug-drug
interactions
To the Editor: As appropriately pointed out in
the review article by Izzedine et al [1], cyclosporine,
tacrolimus, and sirolimus share the same metabolic path-
ways (CYP450 3A4 isoenzyme) as all of the protease
inhibitors (PI) used in treatment of human immunod-
eficiency virus (HIV). However, Table 1 lacks current
information regarding other PIs. Atazanavir sulfate
(Reyataz), FDA approved in June 2003, competi-
tively inhibits CYP3A4, CYP1A2, CYP2C9, uridine
diphosphate-glucuronosyl transferase (UGT) 1A1 en-
zyme, and P-glycoprotein (P-gp) at doses used in current
clinical practice [2, 3]. Although no pharmacokinetic
studies have been completed with the above immuno-
suppressants, it would be reasonable to assume that
atazanavir would cause increases in their plasma levels.
In addition, tipranavir, another PI, is now available
through an expanded access program with Boehringer In-
gelheim while it awaits FDA approval. Unlike other PIs,
tipranavir is an inducer on CYP3A4, thus potentially de-
creasing the levels of these immunosuppressants. How-
ever, the induction of CYP3A4 by tipranavir is lost when
pharmacologically boosted with ritonavir [4]. With the
addition of these two PIs to the market, I felt that it was
important for the readers to also consider this information.
Lastly, Table 1 indicates that enfuviritide (T-20) and
tenofovir (TFV) are PIs. This is incorrect because T-20
is classified as a fusion inhibitor, and tenofovir a nu-
cleotide reverse transcriptase inhibitor. Due to similar
mechanisms of action, tenofovir (a nucleotide reverse
transcriptase inhibitor) is commonly categorized with the
standard nucleoside reverse transcriptase inhibitors
(NRTI). Based on the pharmacokinetic profiles of T-20
and tenofovir, no drug interactions are expected with the
immunosuppressants reviewed.
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Reply from the Authors
We thank Dr. Busti for his interesting comments on
our article [1]. The reason why we decided not to include
atazanavir and tipranavir in our review is that they were
either not available, or very recently released at the time
we wrote this article. We thus thought that more clinical
experience was needed before adding those drugs to such
a review. However, Dr. Busti comments well complete
our article, and we agree with his conclusions.
We totally agree that tenofovir and enfuvirtide have
been misclassified in tables. This obviously results from
an editing error.
Finally, we would not be as confident as Dr. Busti
on the lack of interactions between immunosuppres-
sive and tenofovir or enfuvirtide. Indeed, interactions
through drug transporters in the kidney, the liver, and/or
the intestine are frequent, and because tenofovir inter-
actions with such transporters have been studied, some
other pathways are still under investigation, as well as for
enfuvirtide.
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